A system for preventing and controlling diabetic nephropathy
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
Chinese PLA General Hospital · NCT06843304
This study is trying to create a system to better understand and manage diabetic nephropathy by collecting data on risk factors and symptoms from a large group of people with diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese PLA General Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06843304 on ClinicalTrials.gov |
What this trial studies
This project focuses on diabetic nephropathy, a severe complication of diabetes that leads to significant health issues and resource consumption. It aims to establish a comprehensive regulatory system that covers the entire disease cycle of diabetic nephropathy by integrating large-sample natural population cohorts and prospective follow-up cohorts. The goal is to create a panoramic life database to identify risk factors, clinical phenotypes, and multimodal biomarkers associated with the disease. This approach addresses the current lack of representative cohorts and aims to improve understanding and management of diabetic nephropathy.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of type 2 diabetes for more than 5 years and no proteinuria.
Not a fit: Patients with incomplete medical records, autoimmune diseases, tumors, or those with gestational diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this project could lead to improved prevention and management strategies for diabetic nephropathy, potentially reducing its incidence and severity.
How similar studies have performed: While there is a need for comprehensive studies in this area, the approach of integrating large cohorts is innovative and may not have been extensively tested before.
Eligibility criteria
Show full inclusion / exclusion criteria
T2DM Inclusion Criteria: * Age ≥18 years old, gender is not limited * Diagnosed with type 2 diabetes * A history of type 2 diabetes for more than 5 years * Negative proteinuria * Creatinine is normal * Good compliance, voluntarily sign informed consent Exclusion Criteria: * Incomplete medical records * Lack of fundus microvascular examination or new imaging technology examination results data * Combined with autoimmune diseases and tumors Type 2 diabetes patients undergoing renal biopsy Inclusion Criteria: * Age ≥18 years old, gender is not limited * Diagnosed with type 2 diabetes * Kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency) * Have undergone renal puncture biopsy and have complete renal pathological diagnosis data * Sign informed consent voluntarily Exclusion Criteria: * Gestational diabetes mellitus, special type diabetes mellitus * Patients with hereditary kidney disease * Combined with autoimmune diseases * Diabetic nephropathy The indicators in the comprehensive assessment model of the risk of renal progression could not be obtained * There were pregnancy plans in the study period
Where this trial is running
Beijing, Beijing Municipality
- Chinese PLA General Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Zheyi Dong, MD
- Email: shengdai26@163.com
- Phone: +86 13810261592
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diabetic Nephropathy, T2DM